Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 845 shares of Zai Lab stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total value of $13,241.15. Following the sale, the chief financial officer now directly owns 9,618 shares of the company's stock, valued at $150,714.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Yajing Chen also recently made the following trade(s):
- On Tuesday, April 2nd, Yajing Chen sold 519 shares of Zai Lab stock. The shares were sold at an average price of $16.15, for a total value of $8,381.85.
Zai Lab Trading Up 0.5 %
NASDAQ ZLAB opened at $15.52 on Friday. The business's 50-day moving average price is $19.15 and its two-hundred day moving average price is $23.55. Zai Lab Limited has a 12 month low of $15.24 and a 12 month high of $40.42. The firm has a market capitalization of $1.53 billion, a PE ratio of -4.50 and a beta of 1.10.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.11). Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. The business had revenue of $65.83 million for the quarter, compared to the consensus estimate of $70.41 million. As a group, analysts forecast that Zai Lab Limited will post -3.1 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Zai Lab
Biden out June 13; Kamala won’t replace him?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
Several institutional investors and hedge funds have recently made changes to their positions in the business. 1832 Asset Management L.P. acquired a new position in Zai Lab during the 4th quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. raised its stake in Zai Lab by 68.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,371 shares of the company's stock worth $33,000 after buying an additional 557 shares during the period. PNC Financial Services Group Inc. raised its stake in Zai Lab by 58.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 1,896 shares of the company's stock worth $46,000 after buying an additional 700 shares during the period. BNP Paribas Financial Markets raised its stake in Zai Lab by 45.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,767 shares of the company's stock worth $48,000 after buying an additional 548 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Zai Lab by 1,923.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,550 shares of the company's stock worth $70,000 after buying an additional 2,424 shares during the period. Institutional investors own 41.65% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on ZLAB shares. Morgan Stanley started coverage on Zai Lab in a report on Thursday, December 14th. They issued an "overweight" rating and a $47.50 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zai Lab in a report on Friday, January 12th. Finally, Citigroup dropped their price objective on Zai Lab from $123.00 to $66.00 and set a "buy" rating for the company in a report on Thursday, February 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zai Lab currently has an average rating of "Buy" and an average price target of $64.22.
View Our Latest Stock Report on ZLAB
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
